🔗 Share this article

Given that the United States continues making sweeping changes to its vaccination guidelines, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by casting doubt on COVID-19 vaccines during the global health crisis and has zeroed in on possible fatalities after Covid immunization in her recent tenure at the FDA.

Proposed Changes to Pediatric Immunization Program

Health officials planned to announce sweeping changes to the childhood immunization program earlier this month, bringing the US with the Danish vaccine program, sources say – a substantial departure that would place the US at odds with much of the global community with insufficient data for improved outcomes. This reveal has been delayed until the coming year.

Rather than the director of the vaccine center, Høeg is set to speak at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to lead the center this year.

A Shift at the Agency

Høeg's temporary position could signify a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad solidify control at the agency – and it signals a increased emphasis upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for ending some pediatric immunization guidelines in the US in order to be more in line with the Danish model, a country with nationalized medicine and a number of inhabitants about the population of the state of Wisconsin.

To date statements, she has kept her attention on vaccination policy – usually the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Qualifications

The appointee has no obvious background in medication creation, regulation or management, which has been typical for past directors of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“It seems she lacks to have the requisite experience” for leading the CDER, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She lacks experience in managing a sizeable institution. She has no expertise in industry regulation.”

Former heads of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she lacks the kind of background that former directors who ran the center have had.”

CDER has an immense portfolio at the FDA, she stated.

“The public just focuses on the new drug program, but the generic program approves a multitude of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and so forth, and all of those have to be supervised,” Dr. Woodcock said. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a major administrative component to the role, which oversees over 5,000 staff members. “It’s a huge leadership role, if you perform it correctly,” she said.

Agency Reaction and Disputed Initiatives

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment indicates greater collaboration among agency officials on vaccines, a press secretary stated that the “questions are based on inaccurate presumptions”.

“This background matches the duties of her job,” the representative explained, pointing to the months Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the agency head's new priority voucher program, a contentious one-day therapy clearance system that reportedly troubled her preceding directors. “How are these drugs being selected for this expedited pathway? Who makes the choices?” Howard questioned. “There is a lot of lack of transparency happening at the agency right now.”

In general, he said, “the FDA seems to be moving towards laxer regulations of most medications, except for immunizations.”

Documented Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if troubling, track record, some experts have noted. She released a analysis using non-validated crowd-sourced reports to estimate the frequency of heart inflammation after COVID-19 immunization. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the current government encompassed altering guidelines for recently developed shots and discontinuing “unnecessary” vaccines, she remarked post-election on a online show. At the FDA, Dr. Høeg has according to sources floated the idea of preventing adolescent males from receiving COVID-19 vaccines.

“She is an thorough true believer who begins with her preconceived notions and works backwards to retrofit the evidence in a highly deceptive, fraudulent manner,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg became part of fellow contrarians, {like|